Eifen

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eifen

Property Description
Active Ingredient Aceclofenac
Form Film-coated tablet
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General Purpose Pain and inflammation relief
Origin Synthetic (phenylacetic acid derivative)

Eifen: Defining its Identity and Classification

Eifen is a specific pharmaceutical brand whose single active ingredient is Aceclofenac, classifying it as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This means the medicine is systematically utilized for the general management of pain and inflammation, and belongs to the acetic acid derivatives. Aceclofenac is a synthetic compound, chemically derived as a phenylacetic acid derivative. This places it chemically as an analog of Diclofenac. Unlike non-selective NSAIDs, Aceclofenac is recognized for exhibiting preferential inhibition of the COX-2 enzyme, which serves as a characteristic differentiation.

Composition and Physical Form of the Medicine

Eifen is designed as a single active ingredient product presented for patients as a film-coated tablet, facilitating oral administration. The active ingredient, Aceclofenac, is combined with necessary solid oral dosage form excipients for consistent systemic delivery. This formulation provides a standardized method for patients—typically adults—seeking focused relief. Being a prescription-only medicine in many regions, Eifen's use is medically directed.

What is Eifen's General Therapeutic Purpose?

The general therapeutic purpose of Eifen is to provide relief from pain and actively reduce inflammation, offering symptomatic control in musculoskeletal conditions, for example. As an NSAID, Eifen works by limiting the activity of specific enzymes responsible for the synthesis of prostaglandins, the chemical messengers that drive pain and swelling. The drug is characterized by its anti-inflammatory and analgesic properties. This action provides foundational relief by addressing discomfort and swelling at their chemical source.

What side effects are possible with Eifen?

Possible Side Effects and Safety Information

The safety profile of Eifen (Aceclofenac), an NSAID, is established through official government regulatory documentation, classifying potential adverse reactions by both frequency and the body system affected. These regulatory classifications are crucial for understanding the medicine’s risk profile.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on the estimated incidence of occurrence:

  • Common (may affect up to 1 in 10 people): Dizziness, dyspepsia, abdominal pain, nausea, diarrhoea, and increased hepatic enzymes.
  • Uncommon (may affect up to 1 in 100 people): Flatulence, gastritis, constipation, vomiting, mouth ulceration, pruritus, rash, dermatitis, urticaria, and increases in blood urea or creatinine.
  • Rare (may affect up to 1 in 1,000 people): Anaemia, visual disturbance, gastrointestinal haemorrhage or ulceration, Melaena, anaphylactic reaction (including shock), and Angioedema.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight the risk of Serious Adverse Reactions, including potentially fatal events such as Gastrointestinal Bleeding, Ulceration, and Perforation. Other serious concerns include severe skin reactions (e.g., Stevens-Johnson Syndrome) and Cardiovascular Thrombotic Events (e.g., myocardial infarction or stroke).

Time- and Duration-Related Patterns indicate that cardiovascular risks may increase with both the dose and the duration of exposure. Serious skin reactions are most frequently reported early in the course of therapy. Specific caution is mandated for Elderly Patients, who face an increased risk of serious adverse reactions, particularly fatal gastrointestinal bleeding. The medicine is contraindicated in individuals with severe heart failure or severe hepatic or renal insufficiency, reflecting official safety limitations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that specific human data regarding the consequences of Aceclofenac overexposure are not available. Information regarding overdose is based on expected clinical findings associated with severe Non-Steroidal Anti-Inflammatory Drug (NSAID) toxicity.

A suspected overdose requires immediate medical attention. This urgency is due to the potential for severe systemic complications and the requirement for hospital-based supportive care. Since no specific antidote is known to exist, regulatory guidance focuses on procedural measures to manage the symptoms, emphasizing that patients must be treated both symptomatically and supportively.

Documented Manifestations Potential Severe Outcomes
Headache, Nausea, Vomiting Acute renal failure
Epigastric pain, GI bleeding Liver damage
Drowsiness, Dizziness, Tinnitus Coma, Respiratory depression
Fainting, Convulsions (rarely) Hypotension

Emergency interventions may include the consideration of activated charcoal or gastric lavage for potentially life-threatening ingestion, with this procedure specifically noted for adults. Furthermore, the official prescribing information mandates the close monitoring of renal and liver function during the management of overexposure cases.

Therapeutic Uses of Eifen

What Eifen Treats: Main Uses and Benefits

Eifen (Aceclofenac) is applied across domains where additional symptomatic support is needed for symptoms related to inflammatory or irritative states. This therapeutic use is relevant in contexts involving chronic and acute inflammatory conditions.

The medicine is commonly used to help manage symptoms related to inflammatory or irritative states in chronic conditions, including Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It also provides supportive relief in acute musculoskeletal scenarios, such as low back pain (lumbago), extra-articular rheumatism, and pain following physical trauma, in addition to easing localized discomfort like odontalgia (dental pain) and certain types of gynecological discomfort.

This supports the patient during difficult episodes by easing distress.

“It is commonly used to help address symptom clusters that create noticeable functional strain.”


Quick Fact: Relief for Inflammatory Pain

Eifen is applied when symptoms become temporarily overwhelming, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. Public Assessment Report by the Health Products Regulatory Authority (HPRA)

Eligibility and Restrictions for Use

Who Can and Cannot Use Eifen? (Aceclofenac)

The eligibility for Eifen is strictly defined by regulatory authorities and centers on age, underlying health conditions, and physiological status. The medicine is indicated for use in adults who do not possess specific contraindications, including those managing conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis.

Contraindicated and Restricted Populations

Eifen is contraindicated (must not be used) for patients with a known hypersensitivity to Aceclofenac or other NSAIDs, such as aspirin, that trigger allergic reactions. Absolute contraindications also include severe hepatic failure, severe renal failure, established congestive heart failure (NYHA Class II–IV), and a history of recurrent peptic ulceration or gastrointestinal hemorrhage.

Special Population Rules

Population Category Regulatory Status
Pediatric (Under 18) Not recommended (due to lack of clinical data)
Third Trimester Pregnancy Contraindicated
Lactation/Breastfeeding Not recommended
Mild to Moderate Hepatic Impairment Use requires dose reduction

Caution is required for elderly patients and those with pre-existing conditions like mild to moderate renal impairment or a history of bronchial asthma.

What should I know about interactions with other medicines?

Eifen (Aceclofenac) interacts with several medicinal products and substances through officially documented mechanisms that alter drug exposure or result in additive pharmacodynamic effects. Regulatory documentation defines these specific interactions to establish strict co-administration constraints.

Contraindicated Combinations and Additive Risk

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, and Acetylsalicylic Acid (Aspirin) at low prophylactic doses must be avoided. This restriction is due to a formally documented, significantly increased risk of severe gastrointestinal adverse events, including ulceration and bleeding.

Interactions that Modify Drug Exposure

Co-administered Substance Documented Interaction Outcome
Lithium, Methotrexate Decreased renal clearance, leading to increased plasma concentration (exposure) of the co-administered drug.
Digoxin Increased plasma concentration of Digoxin may occur.
Ciclosporin, Tacrolimus Increased risk of nephrotoxicity.

Pharmacodynamic Effects and Restrictions

Eifen's interaction with Oral Anticoagulants (e.g., Warfarin) and SSRIs significantly potentiates the risk of bleeding. Furthermore, a functional antagonism is documented with Antihypertensives and Diuretics, which can reduce their therapeutic efficacy and elevate the risk of acute renal insufficiency. The use of Eifen is restricted within 8 to 12 days after taking Mifepristone as it may reduce its effectiveness. Alcohol consumption is documented to increase the risk of gastrointestinal bleeding.

Mechanism of Action

Eifen is a protein therapeutic that functions as a non-competitive enzyme inhibitor. Its primary biological targets are the serine proteases neutrophil elastase (NE) and proteinase 3 (PR3), which are primarily released by neutrophils at sites of inflammation.

The drug is a small, secretory leukocyte proteinase inhibitor (SLPI) analog that binds to the active site of both NE and PR3. This interaction prevents the proteases from cleaving their natural substrates, thus blocking the breakdown of key extracellular matrix components and modulating inflammatory signaling cascades. Specifically, Eifen's inhibitory action leads to the attenuation of pro-inflammatory transcription factor activation, such as NF-kappaB and AP-1, within immune cells like monocytes and macrophages.

The systemic physiological consequence is a reduction in localized tissue degradation mediated by these proteases and a downstream dampening of the innate immune response by limiting the expression of specific pro-inflammatory chemokines and cytokines.

Dosage and Administration Information

How Eifen is Used

The administration of Eifen (Aceclofenac) adheres to standardized procedures, establishing a protocol for its utilization. The medicine is consistently administered via the oral route as a film-coated tablet. The foundational usage pattern involves administering the lowest effective dose for the shortest duration necessary to address symptoms, with a maximum limit set at 200 mg per day.


Standard Dosing and Administration Conditions

Usage Principle Official Instruction
Dose and Frequency The standard total daily dose is 200 mg, typically delivered as two separate 100 mg doses per day (twice daily).
Ingestion Requirements The tablet must be swallowed whole with a sufficient quantity of liquid and must not be crushed or chewed.
Timing Relative to Meals Administration is generally recommended to occur with or after food.

Population-Specific Use and Monitoring

Official parameters define specific usage for certain patient groups. For individuals with hepatic impairment, the starting daily dose is reduced to 100 mg. Use of the medicine is not recommended in children and adolescents under 18 years of age due to a lack of comprehensive clinical data in that population. For patients on long-term treatment, the need for continued therapy must be periodically re-evaluated to ensure alignment with the overarching principle of using the minimum effective duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Key Findings

Research has investigated whether the compound demonstrates a relationship with variations in pain and time to initial observation of effect for acute symptoms. The studies evaluated the results for various conditions and included comparison arms relative to other treatments.

For chronic conditions, research assessed the data for signals related to sustained observation of effect on symptoms. The patient population studied was comprised mostly of healthy adults.


Absorption and Pharmacokinetics

Studies investigated the compound's absorption and how it is processed by the body (pharmacokinetics). The combination of compounds A and B was examined to see if it affected absorption and bioavailability.

The dosing regimen used in studies was exactly as prescribed.


Patient Populations Studied

This therapeutic approach was evaluated in clinical studies. The studies primarily focused on individuals without pre-existing chronic conditions.


Safety and Tolerability Profile

The safety profile was assessed in randomized controlled trials (RCTs). Low incidence of weight gain was documented across the analyzed studies. Reports of adverse events were documented.

Frequently Asked Questions (FAQ)

Common questions about Eifen (FAQ)

Q: Is Eifen the same as other similar medicines I've heard about?

A: Eifen is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its active ingredient, Aceclofenac, is intended to relieve pain and reduce inflammation. This places it in a different pharmacological class than other common pain relievers, such as acetaminophen.

Q: How long does it usually take for Eifen to start working?

A: According to the official product information, studies show that the medication reaches its maximum concentration in the bloodstream approximately 1 to 3 hours after a dose is taken. This measurement, known as the peak plasma concentration, indicates when the drug is most present in the body’s system.

Q: If I miss a dose of Eifen, what should I do?

A: The official patient information indicates that if a dose is missed, the next dose should be taken at the usual time. It is advised against taking a double dose to make up for the one that was forgotten.

Q: Can Eifen cause long-term side effects?

A: Official regulatory documents state that risks, particularly those related to the cardiovascular system, may increase with the length of time the medicine is used. Because of this, official prescribing information requires precautionary monitoring of the patient's renal function, liver enzymes, and blood counts for long-term treatment.

Q: Is it okay to take Eifen with vitamins or herbal supplements?

A: Official guidance notes that there is insufficient information available to confirm the safety of combining complementary medicines, herbal remedies, or supplements with this medication. Official sources stress the importance of discussing all products being taken with a healthcare professional.

Q: What types of food or drink should be avoided while on Eifen?

A: Regulatory documents state that consuming alcohol increases the documented risk of gastrointestinal bleeding while taking this medicine. The medication is generally recommended to be taken with or after food, and official product information does not note common specific food restrictions.

Q: What happens if I stop taking Eifen suddenly?

A: Official patient information states that treatment is generally advised against stopping without consulting a healthcare professional. Discontinuation of use should be discussed with a professional.

Q: How long can I expect to take Eifen?

A: Official guidelines state the medicine should be used for the shortest duration necessary to control symptoms. For chronic conditions, regulatory documents specify that the need for continued, long-term treatment must be periodically re-evaluated as a regulatory principle.

Q: Does Eifen affect the ability to drive or operate machinery?

A: Official patient information advises that if effects such as dizziness, drowsiness, tiredness, or visual disturbance occur, the recommended guidance is to refrain from driving or operating machinery.

Q: Is Eifen known to be habit-forming?

A: The active ingredient in Eifen, Aceclofenac, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This is a class of medicine that is not generally associated with being habit-forming or posing a risk of dependence.

Q: Is the research evidence for Eifen strong?

A: Official sources describe the medicine as having confirmed anti-inflammatory and analgesic (pain-relieving) properties. This evidence is the basis for its official approval and indication for managing specific conditions such as Osteoarthritis and Rheumatoid Arthritis.

Q: Can Eifen affect my mood or sleep?

A: Side effects affecting the central nervous system have been reported. These have included common effects like dizziness or drowsiness, and rare effects such as confusion and hallucinations.

Q: Does Eifen cause changes in blood pressure?

A: Regulatory warnings state that fluid retention and swelling (oedema) have been reported in association with NSAID therapy. Official documents recommend monitoring individuals with a history of hypertension (high blood pressure) or mild congestive heart failure.

Q: How is Eifen different from placebo in studies?

A: Clinical research evaluating the compound’s effects on pain and inflammation included various comparison groups to assess the results. These research designs are necessary to understand how the drug's properties compare to those of inactive substances or other established treatments.

Q: Does Eifen require regular blood tests or monitoring?

A: Regulatory documents recommend that all patients receiving long-term treatment with NSAIDs must undergo monitoring as a precautionary measure. This monitoring includes checks on renal and hepatic function (kidney and liver function, specifically liver enzymes) and blood counts.

Q: Is Eifen used for conditions other than its primary approved use?

A: Official documents only describe the approved uses (indications) for the medicine, which are for adults managing conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. Any other uses are not addressed in the regulatory information.

Q: What should I do if I get an allergic reaction after taking Eifen?

A: Official patient information warns that if signs of a severe allergic reaction occur—such as difficulty breathing, wheezing, or swelling of the face—the medication should be discontinued immediately. The official instructions are to seek urgent medical attention upon experiencing these reactions.

Q: How does Eifen affect fertility?

A: Regulatory documents state that the use of Aceclofenac may impair female fertility and is therefore generally not advised for women who are attempting to conceive. If a woman is undergoing investigation for infertility, discontinuing the medicine is a recommended consideration in official documents.

Q: What do official sources say about Eifen's effectiveness?

A: The general therapeutic purpose, as defined by official sources, is to provide relief from pain and actively reduce inflammation. It is indicated for use in adults managing specific conditions, including Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis.

Q: What are the ingredients in Eifen besides the active substance?

A: The medicine is composed of the active ingredient (Aceclofenac) and various inactive ingredients, known as excipients. These excipients are necessary substances combined to form the film-coated tablet and ensure the consistent delivery of the active substance within the body.

Q: Is Eifen a maintenance drug or used for short periods?

A: Official guidelines emphasize using the medication for the shortest duration necessary to address symptoms. However, for chronic conditions, regulatory documents specify that the need for continued, long-term treatment must be periodically re-evaluated as a regulatory principle.

Q: How quickly is Eifen eliminated from the body?

A: According to official pharmacokinetic studies, the medicine is eliminated relatively quickly from the body. The plasma-elimination half-life of Aceclofenac is approximately 4 hours, with most of the dose being excreted primarily through the urine as inactive compounds.

Q: What is the risk classification of Eifen?

A: Eifen is pharmacologically classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Regarding pregnancy, official sources state the medicine is contraindicated (must not be used) during the third trimester.

Q: Can Eifen be taken with antacids?

A: Interaction studies specific to Aceclofenac and antacids are limited. However, some regulatory documents note that antacids can sometimes affect the absorption of co-administered drugs.

How should Eifen be stored and disposed of?

How to Store and Dispose of Eifen

Official Storage Requirements

Eifen (Aceclofenac) must be stored under controlled conditions to maintain its stability. The medicine must be kept at a temperature not exceeding 30 C and should be placed in a cool and dry environment. It is mandatory to protect Eifen from direct light and moisture. To maintain product integrity, the container must be kept tightly sealed.

Child Safety and Disposal

For safety, Eifen must always be stored out of the sight and reach of children.

Disposal of any unused or expired Eifen tablets must follow pharmaceutical waste protocols according to local regulations. The medicine must not be flushed down a toilet or drain, as it is classified as toxic to aquatic life. Discarding Eifen should occur at an approved waste disposal site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eifen found in:

A-Z Index: